<DOC>
	<DOCNO>NCT01999413</DOCNO>
	<brief_summary>Pilot study efficacy tolerance adjunction Fish oil emulsion daunorubicin cytarabine chemotherapy treatment Acute MYeloblastic Leukemia Younger patient ( 61 year ) high-risk cytogenetics .</brief_summary>
	<brief_title>Pilot Study Efficacy Tolerance Fish Oil Emulsion Daunorubicin Cytarabine Treatment AML Younger Patients</brief_title>
	<detailed_description>Adjunction Fish oil emulsion OMEGAVEN daunorubicin cytarabine chemotherapy treatment Acute MYeloblastic Leukemia Younger patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patient 18 60 year old ( less 61 year old ) With newly diagnose AML accord WHO classification : With 20 % blast bone marrow Patients history tumor myeloproliferative disorder myelodysplastic syndrome , receive chemotherapy and/or radiotherapy without previous history myelodysplastic syndrome eligible present study Highrisk cytogenetics define one follow abnormality : 5/5q , 7/7q , ( 6,9 ) , 11q23 abnormality excluding ( 9 ; 11 ) , 3q abnormality , complex karyotype ( &gt; 3 abnormalites ) Left ventricular ejection fraction ( LVEF ) &gt; 50 % echocardiography multigated acquisition ( MUGA ) scan similar radionuclide angiographic scan . Adequate liver function ( follow ) except secondary leukemia : Total bilirubin 1.5 x upper limit normal ( ULN ) , AST ALT 2.5 x ULN , gammaGT 2.5 x ULN , Adequate kidney function ( follow ) : Serum creatinine 1.5 x ULN , Creatinine clearance 50 mL/min ( Cockroft Gault formula ) ECOG performance status &lt; = 2 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . The patient must give write ( personally sign date ) inform consent complete studyrelated procedure mean assessment evaluation would form part normal medical care patient . Affiliated French Social Security ( Health Insurance ) . Previous allogeneic stem cell transplantation . Preexisting aplastic anemia Presence favourable cytogenetics ( 8 ; 21 ) , ( 15 ; 17 ) , inv ( 16 ) Previous history MDS myeloproliferative neoplasm Uncontrolled active infection . History arrythmia . Cardiac toxicity induce another anthracycline administration Maximum cumulative dose reach anthracyclin Allergy cytarabine , daunorubicin , fish egg proteins10 . Significant neurologic ( grade &gt; 2 ) psychiatric disorder , dementia seizure . Clinical symptom suggest active central nervous system leukemia . Degenerative toxic encephalopathy Severe complication leukemia : Uncontrolled bleeding , Pneumonia hypoxia shock Prior total body irradiation &gt; 10 Gy . Known active HIV , Hepatitis B C infection Pregnancy breastfeed Concomitant antiamarile vaccination ( yellow fever ) Concurrent treatment anticancer therapy except Hydroxyurea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>high-risk cytogenetics</keyword>
	<keyword>young patient</keyword>
	<keyword>Induction treatment</keyword>
	<keyword>OMEGAVEN</keyword>
</DOC>